HC Wainwright Reiterates "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $53.00 price target on the biopharmaceutical company's stock. HC Wainwright's price objective points to a potential upside of 74.98% from the company's previous close. HC Wainwright also issued estimates for Xenon Pharmaceuticals' Q2 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.48) EPS, Q2 2026 earnings at ($1.34) EPS, FY2026 earnings at ($5.38) EPS, FY2027 earnings at ($5.70) EPS, FY2028 earnings at ($5.11) EPS and FY2029 earnings at ($3.61) EPS.

XENE has been the topic of a number of other reports. The Goldman Sachs Group decreased their price objective on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Chardan Capital reiterated a "buy" rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, May 13th. Royal Bank of Canada restated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. StockNews.com lowered shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, May 2nd. Finally, Needham & Company LLC lowered their price target on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat, Xenon Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $54.82.

Xenon Pharmaceuticals Trading Up 2.4%

Shares of Xenon Pharmaceuticals stock traded up $0.72 on Tuesday, hitting $30.29. 966,331 shares of the company traded hands, compared to its average volume of 511,566. The firm's 50-day simple moving average is $34.10 and its 200 day simple moving average is $37.93. The company has a market cap of $2.32 billion, a P/E ratio of -10.74 and a beta of 1.21. Xenon Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. The firm had revenue of $7.50 million during the quarter, compared to the consensus estimate of $1.64 million. During the same period in the prior year, the company earned ($0.62) EPS. Analysts predict that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.

Hedge Funds Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the first quarter worth about $30,000. GF Fund Management CO. LTD. purchased a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $63,000. Quarry LP bought a new position in Xenon Pharmaceuticals during the 4th quarter valued at approximately $78,000. Blue Trust Inc. lifted its holdings in Xenon Pharmaceuticals by 140.3% in the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock worth $95,000 after buying an additional 1,414 shares during the period. Finally, Avior Wealth Management LLC bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $101,000. Hedge funds and other institutional investors own 95.45% of the company's stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.